Direct comparison of in vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA with that of 2′-O-(2-methoxy)ethyl-modified oligonucleotides

Oligonucleotides

Volumn 16, Issue 3, 2006, Pages 253-262

  Koizumi, Makoto ^a   Takagi Sato, Miho ^a   Okuyama, Ryo ^a   Araki, Kazushi ^a   Sun, Weiyong ^a   Nakai, Daisuke ^a   Tsutsumi, Shinya ^a   Kawai, Kenji ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2' O (2 METHOXY)ETHYL OLIGONUCLEOTIDE; 2' O,4 C ETHYLENE NUCLEIC ACID; ANTISENSE OLIGODEOXYNUCLEOTIDE; BRIDGED COMPOUND; GLUCOSE; INSULIN; ISIS 113715; MESSENGER RNA; NUCLEOSIDE DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE 1B; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DNA MODIFICATION; DOWN REGULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; GENE; GENE EXPRESSION REGULATION; GENE TARGETING; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; INSULIN SENSITIVITY; LIVER; MALE; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PTP1B GENE;

ANIMALS; HEAT; MALE; MICE; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTORS, CELL SURFACE; RNA, ANTISENSE; RNA, MESSENGER;

EID: 33751083352     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2006.16.253     Document Type: Article

References (38)

1. ACHENBACH, T.V., BRUNNER, B., and HEERMEIER, K. (2003). Oligonucleotide-based knockdown technologies: Antisense versus RNA interference. Chembiochem 4, 928-935.
2. BERTRAND, J.R., POTTIER, M., VEKRIS, A., OPOLON, P., MAKSIMENKO, A., and MALVY, C. (2002). Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 296, 1000-1004.
3. BUTLER, M., MCKAY, R.A., POPOFF, I.J., GAARDE, W.A., WITCHELL, D., MURRAY, S.F., DEAN, N.M., BHANOT, S., and MONIA, B.P. (2002). Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 51, 1028-1034.
4. CROOKE, R.M., GRAHAM, M.J., LEMONIDIS, K.M., WHIPPLE, C.P., KOO, S., and PERERA, R.J. (2005). An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46, 872-884.
5. DYKXHOORN, D.M., NOVINA, C.D., and SHARP, P.A. (2003). Killing the messenger: Short RNAs that silence gene expression. Nat. Rev. Mol. Cell. Biol. 4, 457-467.
6. ELCHEBLY, M., PAYETTE, P., MICHALISZYN, E., CROMLISH, W., COLLINS, S., LOY, A.L., NORMANDIN, D., CHENG, A., HIMMS-HAGEN, J., CHAN, C.C., RAMACHANDRAN, C., GRESSER, M.J., TREMBLAY, M.L., and KENNEDY, B.P. (1999). Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283, 1544-1548.
7. GEARY, R.S., WATANABE, T.A., TRUONG, L., FREIER, S., LESNIK, E.A., SIOUFI, N.B., SASMOR, H., MANOHARAN, M., and LEVIN, A.A. (2001). Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296, 890-897.
8. GEARY, R.S., HENRY, S.P., and GRILLONE, L.R. (2002). Fomivirsen: Clinical pharmacology and potential drug interactions. Clin. Pharmacokinet. 41, 255-260.
9. GRAHAM, M.J., FREIER, S.M., CROOKE, R.M., ECKER, D.J., MASLOVA, R.N., and LESNIK, E.A. (1993). Tritium labeling of antisense oligonucleotides by exchange with tritiated water. Nucleic Acids Res. 21, 3737-3743.
10. GRUNWELLER, A., WYSZKO, E., BIEBER, B., JAHNEL, R., ERDMANN, V.A., and KURRECK, J. (2003). Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 31, 3185-3193.
11. HANNON, G.J. (2002). RNA interference. Nature 418, 244-251.
12. HERBERT, B.S., GELLERT, G.C., HOCHREITER, A., PONGRACZ, K., WRIGHT, W.E., ZIELINSKA, D., CHIN, A.C., HARLEY, C.B., SHAY, J.W., and GRYAZNOV, S.M. (2005). Lipid modification of GRN163, an N3′-P5′ thiophosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24, 5262-5268.
13. HORIE, M., MORITA, K., KAWAKAMI, J., TSUTSUMI, S., ANDO, O., and KOIZUMI, M. (2006). Comparison between properties of 2′-O,4′-C-ethylene- bridged nucleic acid (ENA®) phosphorothioate oligonucleotides and N3′-P5′ thiophosphoramidate oligonucleotides. Nucleosides, Nucleotides Nucleic Acids 25, 231-242.
14. IVERSEN, P.L., ARORA, V., ACKER, A.J., MASON, D.H., and DEVI, G.R. (2003). Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase I safety study in humans. Clin. Cancer Res. 9, 2510-2519.
15. KENNER, K.A., ANYANWU, E., OLEFSKY, J.M., and KUSARI, J. (1996). Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling. J. Biol. Chem. 271, 19810-19806.
16. KOIZUMI, M., MORITA, M., DAIGO, M., TSUTSUMI, S., ABE, K., OBIKA, S., and IMANISHI, T. (2003). Triplex formation with 2′-O,4′-C-ethylene- bridged nucleic acids (ENA) having C3′-endo conformation at physiological pH. Nucleic Acids Res. 31, 3267-3273.
17. KOSHKIN, A.A., SINGH, S.K., NIELSEN, P., RAJWANSHI, V.K., KUMAR, R., MELDGAARD, M., OLSEN, C.E., and WENGEL, J. (1998). LNA (locked nucleic acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54, 3607-3630.
18. LIU, G. (2004). Technology evaluation: ISIS-113715, Isis. Curr. Opin. Mol. Ther. 6, 331-336.
19. MARTIN, P. (1995). Ein neuer Zugang 2′-O-Alkylribonucleosiden und Eigenschaften deren Oligonucleotide. Helv. Chim. Acta 78, 486-504.
20. MORITA, K., HASEGAWA, C., KANEKO, M., TSUTSUMI, S., SONE, J., ISHIKAWA, T., IMANISHI, T., and KOIZUMI, M. (2002a). 2′-O,4′-C-Ethylene- bridged nucleic acids (ENA): Highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg. Med. Chem. Lett. 12, 73-76.
21. MORITA, K., YAMATE, K., KURAKATA, S., ABE, K., IMANISHI, T., and KOIZUMI, M. (2002b). Down-regulation of VEGF mRNA expression by 2′-O,4′-C- ethylene-bridged nucleic acid (ENA) antisense oligonucleotides and investigation of non-target gene expression. Nucleic Acids Res. Suppl. 2, 99-100.
22. MORITA, K., TAKAGI, M., HASEGAWA, C., KANEKO, M., TSUTSUMI, S., SONE, J., ISHIKAWA, T., IMANISHI, T., and KOIZUMI, M. (2003). Synthesis and properties of 2′-O,4′-C-ethylene-bridged nucleic acids (ENA) as effective antisense oligonucleotides. Bioorg. Med. Chem. 11, 2211-2226.
23. OBIKA, S., NANBU, D., HARI, Y., MORIO, K., IN, Y., ISHIDA, T., and IMANISHI, T. (1997). Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine: Novel bicyclic nucleosides having a fixed C3′-endo sugar puckering. Tetrahedron Lett. 38, 8735-8738.
24. OBIKA, S., UNEDA, T., SUGIMOTO, T., NANBU, D., MINAMI, T., DOI, T., and IMANISHI, T. (2001). 2′-O,4′-C-Methylene bridged nucleic acid (2′,4′-BNA): Synthesis and triplex-forming properties. Bioorg. Med. Chem. 9, 1001-1011.
25. ORUM, H. (2005). Engineering genomics: RNA antagonists-a new class of antisense drugs. IEEE Eng. Med. Biol. Mag. 24, 81-87.
26. PHILLIPS, J.A., CRAIG, S.J., BAYLEY, D., CHRISTIAN, R.A., GEARY, R., and NICKLIN, P.L. (1997). Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol. 54, 657-668.
27. SAZANI, P., GEMIGNANI, F., KANG, S.H., MAIER, M.A., MANOHARAN, M., PERSMARK, M., BORTNER, D., and KOLE, R. (2002). Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20, 1228-1233.
28. L expression and facilitates tumor cell apoptosis. Oligonucleotides 14, 199-209.
29. SLEDZ, C.A., HOLKO, M., DE VEER, M.J., SILVERMAN, R.H., and WILLIAMS, B.R. (2003). Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 834-839.
30. SOUTSCHEK, J., AKINC, A., BRAMLAGE, B., CHARISSE, K., CONSTIEN, R., DONOGHUE, M., ELBASHIR, S., GEICK, A., HADWIGER, P., HARBORTH, J., JOHN, M., KESAVAN, V., LAVINE, G., PANDEY, R.K., RACIE, T., RAJEEV, K.G., ROHL, I., TOUDJARSKA, I., WANG, G., WUSCHKO, S., BUMCROT, D., KOTELIANSKY, V., LIMMER, S., MANOHARAN, M., and VORNLOCHER, H.P. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178.
31. SURONO, A., VAN KHANH, T., TAKESHIMA, Y., WADA, H., YAGI, M., TAKAGI, M., KOIZUMI, M., and MATSUO, M. (2004). Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of Duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon. Hum. Gene Ther. 15, 749-757.
32. TAKAGI, M., MORITA, K., NAKAI, D., NAKAGOMI, R., TOKUI, T., and KOIZUMI, M. (2004). Enhancement of the inhibitory activity of oatp antisense oligonucleotides by incorporation of 2′-O,4′-C-ethylene-bridged nucleic acids (ENA) without a loss of subtype selectivity. Biochemistry 43, 4501-4510.
33. VICKERS, T.A., KOO, S., BENNETT, C.F., CROOKE, S.T., DEAN, N.M., and BAKER, B.F. (2003). Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents: A comparative analysis. J. Biol. Chem. 278, 7108-7118.
34. WANG, H., HANG, J., SHI, Z., LI, M., YU, D., KANDIMALLA, E.R., AGRAWAL, S., and ZHANG, R. (2002). Antisense oligonucleotide targeted to RIα subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int. J. Oncol. 21, 73-80.
35. WINKLER, K.E. (2004). Killing the messenger. Nat. Rev. Drug Discov. 3, 823-824.
36. YU, X.X., MURRAY, S.F., PANDEY, S.K., BOOTEN, S.L., BAO, D., SONG, X.Z., KELLY, S., CHEN, S., MCKAY, R., MONIA, B.P., and BHANOT, S. (2005). Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42, 362-371.
37. ZHANG, H., COOK, J., NICKEL, J., YU, R., STECKER, K., MYERS, K., and DEAN, N.M. (2000). Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotechnol. 18, 862-867.
38. ZINKER, B.A., RONDINONE, C.M., TREVILLYAN, J.M., GUM, R.J., CLAMPIT, J.E., WARING, J.F., XIE, N., WILCOX, D., JACOBSON, P., FROST, L., KROEGER, P.E., REILLY, R.M., KOTERSKI, S., OPGENORTH, T.J., ULRICH, R.G., CROSBY, S., BUTLER, M., MURRAY, S.F., MCKAY, R.A., BHANOT, S., MONIA, B.P., and JIROUSEK, M.R. (2002). PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 99, 11357-11362.